Distinguishing androgen receptor agonists and antagonists: Distinct mechanisms of activation by medroxyprogesterone acetate and dihydrotestosterone

Molecular Endocrinology

Volumn 13, Issue 3, 1999, Pages 440-454

  Kemppainen, Jon A ^a   Langley, Elizabeth ^a,c   Wong, Choi iok ^a   Bobseine, Kathy ^b   Kelce, William R ^b,d   Wilson, Elizabeth M ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^c UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^d MONSANTO COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANTIANDROGEN; CYPROTERONE ACETATE; ESTRADIOL; FLUOXYMESTERONE; HYDROXYFLUTAMIDE; MEDROXYPROGESTERONE ACETATE; METRIBOLONE; MIBOLERONE; OXANDROLONE; RU 56187; TESTOSTERONE; UNCLASSIFIED DRUG;

ARTICLE; CARBOXY TERMINAL SEQUENCE; COMPLEX FORMATION; DIMERIZATION; DNA BINDING; HORMONE RECEPTOR INTERACTION; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION;

MAMMARY TUMOR VIRUS; MOUSE MAMMARY TUMOR VIRUS; TUMOR VIRUS;

EID: 0032935119     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/mend.13.3.0255     Document Type: Article

References (67)

1. 1. Kelce WR, Stone CR, Laws SC, Gray LE, Kemppainen JA, Wilson EM 1995 Persistent DDT metabolite p,p'-DDE is a potent androgen receptor antagonist. Nature 375:581-585
2. 2. Kelce WR, Wilson EM 1997 Environmental antiandrogens: developmental effects, molecular mechanisms and clinical implications. J Mol Med 75:198-207
3. 3. Gittes RF 1991 Carcinoma of the prostate. N Engl J Med 324:236-245
4. 4. Langley E, Zhou ZX, Wilson EM 1995 Evidence for an anti-parallel orientation of the ligand-activated human androgen receptor dimer. J Biol Chem 270:29983-29990
5. 5. Kraus WL, McInerney EM, Katzenellenbogen BS 1995 Ligand-dependent, transcriptionally productive association of the amino- and carboxyl-terminal regions of a steroid hormone nuclear receptor. Proc Natl Acad Sci USA 92:12314-12318
6. 2-/carboxyl-terminal interactions in androgen receptor dimerization revealed by mutations that cause androgen insensitivity. J Biol Chem 273:92-101
7. 3H]-methyltrienolone to both progestin and androgen binding components in human benign prostatic hypertrophy (BPH). J Steroid Biochem 10:483-486
8. 8. Raynaud JP, Ojasoo T, Bouton MM, Philibert D 1979 Receptor binding as a tool in the development of new bioactive steroids. In: Ariens EJ (ed) Drug Design. Academic Press, New York, vol 8:169-214
9. 3H-methyltrienolone (R1881) in the presence of progesterone receptors. Endocrinology 104:1007-1012
10. 3H]19-nortestosterone for the estimation of androgen receptor in rat liver cytosol. J Steroid Biochem 23:121-123
11. 11. Bardin CW, Brown T, Isomaa W, Janne OA 1984 Progestins can mimic, inhibit and potentiate the actions of androgens. Pharmacol Ther 23:443-459
12. 12. Mowszowicz I, Bieber DE, Chung KW, Bullock LP, Bardin CW 1974 Synandrogenic and antiandrogenic effect of progestins: comparison with nonprogestational antiandrogens. Endocrinology 95:1589-1599
13. 13. Raynaud JP, Bouton MM, Moguilewsky M, Ojasoo T, Philibert D, Beck G, Labrie F, Mornon JP 1980 Steroid hormone receptors and pharmacology. J Steroid Biochem 12:143-157
14. 14. Teutsch G, Goubet F, Battmann T, Bonfils A, Bouchoux F, Cerede E, Gofflo D, Gaillard-Kelly M, Philibert D 1994 Non-steroidal antiandrogens: synthesis and biological profile of high-affinity ligands for the androgen receptor. J Steroid Biochem Mol Biol 48:111-119
15. 15. Battmann T, Bonfils A, Branche C, Humbert J, Goubet F, Teutsch G, Philibert D 1994 RU 58841, a new specific topical antiandrogen: a candidate of choice for the treatment of acne, androgenic alopecia and hirsutism. J Steroid Biochem Mol Biol 48:55-60
16. 16. Kemppainen JA, Wilson EM 1996 Agonist and antagonist activities of hydroxyflutamide and casodex relate to androgen receptor stabilization. Urology 48:157-163
17. 17. Schule R, Muller M, Kaltschmidt C, Renkawitz R 1988 Many transcription factors interact synergistically with steroid receptors. Science 242:1418-1420
18. 18. Nordeen SK 1988 Luciferase reporter gene vectors for analysis of promoters and enhancers. Biotechniques 6:454-458
19. 19. Labrie C, Simard J, Zhao HF, Pelletier G, Labrie F 1990 Synthetic progestins stimulate prostatic binding protein messenger RNAs in the rat ventral prostate. Mol Cell Endocrinol 68:169-179
20. 20. De Bellis A, Quigley CA, Marschke KB, El-Awady MK, Lane MV, Smith EP, Sar M, Wilson EM, French FS 1994 Characterization of mutant androgen receptors causing partial androgen insensitivity syndrome. J Clin Endocrinol Metab 78:513-522
21. 21. Yarbrough WG, Quarmby VE, Simental JA, Joseph DR, Sar M, Lubahn DB, Olsen KL, French FS, Wilson EM 1990 A single base mutation in the androgen receptor gene causes androgen insensitivity in the Tfm rat. J Biol Chem 265:8893-8900
22. 22. Zhou ZX, Lane MV, Kemppainen JA, French FS, Wilson EM 1995 Specificity of ligand dependent androgen receptor stabilization: receptor domain interactions influence ligand dissociation and receptor stability. Mol Endocrinol 9:208-218
23. 23. Deleted in proof
24. 24. Archer TK, Fryer CJ, Lee HL, Zaniewski E, Liang T, Mymryk JS 1995 Steroid hormone receptor status defines the MMTV promoter chromatin structure in vivo. J Steroid Biochem Mol Biol 53:1-6
25. 2-terminal and steroid binding domains. J Biol Chem 268:19004-19012
26. 26. Wong CI, Kelce WR, Sar M, Wilson EM 1995 Androgen receptor antagonist versus agonist activities of the fungicide vinclozolin relative to hydroxyflutamide. J Biol Chem 270:19998-20003
27. 27. Kemppainen JA, Lane MV, Sar M, Wilson EM 1992 Androgen receptor phosphorylation, turnover, nuclear transport and transcriptional activation: specificity for steroids and antihormones. J Biol Chem 267:968-974
28. 28. Pérez-Palacios G, Chvez B, Vilchis F, Escobar N, Larrea F, Pérez AE 1983 Interaction of medroxyprogesterone acetate with cytosol androgen receptors in the rat hypothalamus and pituitary. J Steroid Biochem 19:1729-1735
29. 29. Bullock LP, Bardin CW, Sherman MR 1978 Androgenic, antiandrogenic, and synandrogenic actions of progestins: role of steric and allosteric interactions with androgen receptors. Endocrinology 103:1768-1782
30. 30. Brown TR, Bullock LP, Bardin CW 1979 In vivo metabolism and binding of 6α-methylprogesterone: a progestin with anti-androgenic and synandrogenic activities. In: Clark JH, Leavitt WW (eds) Steroid Hormone Receptor Systems. Plenum, New York, pp 269-280
31. 31. Raynaud JP, Bonne C, Bouton MM, Lagace L, Labrie F 1979 Action of a non-steroidal antiandrogen, RU 23908, in peripheral and central tissues. J Steroid Biochem 11:93-99
32. 32. Duax WL, Cody V, Griffin J, Hazel J, Weeks CM 1978 Steroid structure and function. II. Conformational transmission and receptor binding of medroxyprogesterone acetate. J Steroid Biochem 9:901-907
33. 33. Ojasoo T, Delettré 8 J, Mornon JP, Turpin-VanDycke C, Raynaud JP 1987 Towards the mapping of the progesterone and androgen receptors. J Steroid Biochem 27:255-269
34. 34. Terenius L 1974 Affinities of progestogen and estrogen receptors in rabbit uterus for synthetic progestins. Steroids 23:909-918
35. 35. Richman RA, Underwood LE, French FS, Van Wyk JJ 1971 Adverse effects of large doses of medroxyprogesterone (MPA) in idiopathic isosexual precocity. J Pediatr 79:963-971
36. 36. Barlow SM 1982 Medroxyprogesterone in in vitro fertilization. Lancet 2:1408
37. 37. Barlow SM, Knight AF 1983 Teratogenic effects of Silastic intrauterine devices in the rat with or without added medroxyprogesterone acetate. Fertil Steril 39:224-230
38. 38. Gorski RA 1971 Gonadal hormones and the perinatal development of neuroendocrine function. In: Martini L, Ganong WF (eds) Frontiers in Neuroendocrinology. Oxford University Press, New York, pp 237-282
39. 39. Schardein JL 1980 Congenital abnormalities and hormones during pregnancy: a clinical review. Teratology 22:251-270
40. 40. Teulings FAG, van Gilse HA, Henkelman MS, Portengen H, Alexieva-Figusch J 1980 Estrogen, androgen, glucocorticoid, and progesterone receptors in progestin-induced regression of human breast cancer. Cancer Res 40:2557-2561
41. 41. Young PCM, Keen FK, Einhorn LH, Stanick BM, Ehrlich CE, Cleary RE 1980 Binding of medroxyprogesterone acetate in human breast cancer. Am J Obstet Gynecol 137:284-292
42. 42. Hackenberg R, Hawighorst T, Filmer A, Nia AH, Schulz KD 1993 Medroxyprogesterone acetate inhibits the proliferation of estrogen and progesterone receptor negative MFM-223 human mammary cancer cells via the androgen receptor. Breast Cancer Res Treat 25:217-224
43. 43. Birrell SN, Roder DM, Horsfall DJ, Bentel JM, Tilley WD 1995 Medroxyprogesterone acetate therapy in advanced breast cancer: the predictive value of androgen receptor expression. J Clin Oncol 13:1572-1577
44. 44. Couture P, Thériault C, Simard J, Labrie F 1993 Androgen receptor mediated stimulation of 17α-hydroxysteroid dehydrogenase activity by dihydrotestosterone and medroxyprogesterone acetate in ZR-75-1 human breast cancer cells. Endocrinology 132:179-185
45. 45. Waskiewicz MJ, Choudhuri S, Vanderbeck SM, Zhang XJ, Thomas PE 1995 Induction of male specific cytochrome P450 isozymes in female rats by oxandrolone. Drug Metab Dispos 23:1291-1296
46. 46. Levien TL, Baker DE 1994 Reviews of trimetrexate and oxandrolone. Hosp Pharm 29:696-707
47. 47. Stanhope S, Brook C 1985 Oxandrolone in low dose for constitutional delay of growth and puberty in boys. Arch Dis Child 60:379-381
48. 48. Hochberg Z, Korman S 1987 Oxandrolone therapy in boys of short stature. J Pediatr Endocrinol 2:115-120
49. 49. Strickland AL 1993 Long-term results of treatment with low-dose fluoxymesterone in constitutional delay of growth and puberty and in genetic short stature. Pediatrics 91:716-720
50. 50. Urban M, Lee P, Dorst J, Plotnick M, Migeon C 1979 Oxandrolone therapy in patients with Turner's syndrome. J Pediatr 94:823-827
51. 51. Haeusler G, Frisch H, Schmitt K, Blümel P, Plöchl E, Zachmann, Waldhör T 1995 Treatment of patients with Ullrich-Turner syndrome with conventional doses of growth hormone and the combination with testosterone or oxandrolone: effect on growth, IGF-1 and IGFBP-3 concentrations. Eur J Pediatr 154:437-444
52. 52. Renaud JP, Rochel N, Ruff M, Vivat V, Chambon P, Gronemeyer H, Moras D 1995 Crystal structure of the RAR-γ ligand-binding domain bound to all-trans retinoic acid. Nature 378:681-689
53. 53. Wagner RL, Apriletti JW, McGrath ME, West BL, Baxter JD, Fletterick RJ 1995 A structural role for hormone in the thyroid hormone receptor. Nature 378:690-699
54. 54. Brzozowski AM, Pike ACW, Dauter Z, Hubbard RE, Bonn T, Engström O, Öhman L, Greene GL, Gustafsson JA, Carlquist M 1997 Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389:753-758
55. 55. Bourguet W, Ruff M, Chambon P, Gronemeyer H, Moras D 1995 Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-α. Nature 375:377-382
56. 56. Quigley CA, De Bellis A, Marschke KB, El-Awady MK, Wilson EM, French FS 1995 Androgen receptor defects: historical, clinical and molecular perspectives. Endocr Rev 16:271-321
57. 57. Doesburg P, Kuil CW, Berrevoets CA, Steketee K, Faber PW, Mulder E, Brinkmann AO, Trapman J 1997 Functional in vivo interaction between the amino-terminal, transactivation domain and the ligand binding domain of the androgen receptor. Biochemistry 36:1052-1064
58. 58. Tetel MJ, Jung S, Carbajo P, Ladtkow T, Skafar DF, Edwards DP 1997 Hinge and amino-terminal sequences contribute to solution dimerization of human progesterone receptor. Mol Endocrinol 11:1114-1128
59. 59. Kelce WR, Monosson E, Gamcsik MP, Laws SC, Gray LE 1994 Environmental hormone disruptors: evidence that vinclozolin developmental toxicity is mediated by antiandrogenic metabolites. Toxicol Appl Pharmacol 126:276-285
60. 60. Lillie JW, Green MR 1989 Transcription activation by the adenovirus E1a protein. Nature 338:39-44
61. 61. Tan JA, Marschke KB, Ho KC, Perry ST, Wilson EM, French FS 1992 Response elements of the androgen regulated C3 gene. J Biol Chem 267:4456-4466
62. 62. Wilson EM, French FS 1976 Binding properties of androgen receptors: evidence for identical receptors in rat testis, epididymis and prostate. J Biol Chem 251:5620-5629
63. 63. Schilling K, Liao S 1984 The use of radioactive 7α, 17α-dimethyl-19-nortestosterone (mibolerone) in the assay of androgen receptors. Prostate 5:581-588
64. 64. Bonne C, Raynaud JP 1975 Methyltrienolone, a specific ligand for cellular androgen receptors. Steroids 26:227-232
65. 65. Fang S, Liao S 1969 Antagonistic action of anti-androgens on the formation of a specific dihydrotestosterone-receptor protein complex in rat ventral prostate. Mol Pharmacol 5:428-431
66. 66. Neri R, Florance K, Koziol P, S Van Cleave 1972 A biological profile of a nonsteroidal antiandrogen, SCH 13521 (4′-nitro-3′-trifluoromethylisobutyranilide). Endocrinology 91:427-437
67. 67. Liao S, Howell DK, Chang TM 1974 Action of a nonsteroidal antiandrogen, flutamide, on the receptor binding and nuclear retention of 5α-dihydrotestosterone in rat ventral prostate. Endocrinology 94:1205-1209